logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Post-kala-azar dermal leishmaniasis (PKDL): a prospective observational study of the effectiveness and safety of an ambulatory short course treatment with AmBisome* 15 mg/kg total dose | Protocol / Research Protocol | MSF Science Portal
Protocol
|Research Protocol

Post-kala-azar dermal leishmaniasis (PKDL): a prospective observational study of the effectiveness and safety of an ambulatory short course treatment with AmBisome* 15 mg/kg total dose

Ritmeijer KKD
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
General objective
To evaluate the effectiveness and safety of PKDL treatment with AmBisome 15 mg/kg total dose, given over 15 days in 5 infusions (twice weekly) of 3mg/kg on an ambulatory basis in a primary health care setting.

Primary objective: to evaluate the effectiveness of AmBisome 15 mg/kg total dose at 12 M

Secondary objective:
• Evaluate the safety of AmBisome 3mg/kg x 5 infusions (twice weekly) (15 mg/kg total dose)
• Evaluate the occurrence of hypokalaemia
• Evaluate at which point in time lesions start to respond to treatment.

Subject Area

neglected tropical diseasesleishmaniasis

Languages

English
Published Date
01 Jun 2014